Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: TX000045- Dose A, TX000045- Dose B, Placebo; Drug
Lead sponsor: Tectonic Therapeutic; Industry
Eligibility: 18 Years to 83 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Background PAH Therapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico

Conditions: Pulmonary Arterial Hypertension
Interventions: 18F-FGLN PET Imaging, (18F)FPGLU; Diagnostic Test · Drug
Lead sponsor: Stephen Y. Chan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: ATACAND; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 42
States / cities: Mobile, Alabama • Long Beach, California • Redondo Beach, California + 39 more

Conditions: Pulmonary Arterial Hypertension
Interventions: PAH Therapies; Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: Hypertension
Interventions: Enhanced health education, Transcendental Meditation program; Behavioral
Lead sponsor: Maharishi International University; Other
Eligibility: 40 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperlipemia, Hypertension, Type2 Diabetes
Interventions: Text Message Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Intervention Values Affirmation, Control Values Affirmation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 100 Years
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Denver, Colorado • Rockville, Maryland

Conditions: Hypertension
Interventions: carvedilol; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, Blood Pressure
Interventions: Pharmacist Drug Therapy Management; Other
Lead sponsor: University of Louisiana Monroe; Other
Eligibility: 4 Years to 20 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: West Monroe, Louisiana

Conditions: Aging, Medication Adherence, Hypertension
Interventions: Blood Pressure Technology System M, Blood Pressure Technology System E; Other
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Tucson, Arizona • Champaign, Illinois

Conditions: Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions: Ranibizumab, No Ranibizumab; Drug · Other
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Hypertension
Interventions: Device under test evaluation against references; Device
Lead sponsor: Aktiia SA; Industry
Eligibility: 22 Years to 59 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions: LTP, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Orange, California • Stanford, California + 16 more

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Obesity, Hypertension
Interventions: Lifestyle Modification Program, Usual Care and Reading Materials; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Telmisartan, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 19 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Supine Applanating Prototype; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Hypertension
Interventions: NOTES, AUDIO; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas

Conditions: Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
Interventions: grape seed extract (MegaNatural BP, Polyphenolics, Inc.); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Open Angle Glaucoma
Interventions: Acular LS, Pred Forte, Refresh Tears; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity (Disorder), Diabetes Type 2, Heart Disease, Hypertension, Cancer, High Cholesterol
Interventions: Nutrition Education and Food Delivery, Physical Activity Comparator; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Hypertension medication algorithm, Impedance Cardiography; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 26
States / cities: Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 20 more

Search by objective public record fields.

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

PET Image in PAH Patients

TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

Evaluating Mechanisms of Blood Pressure Reduction Using Meditation in Hypertensive African Americans

A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions

The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial

Conditioned Pharmacotherapeutic Effects in Hypertension

Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric Hypertension

Improving Hypertension Medication Adherence for Older Adults

Analysis of Aqueous and Vitreous Humor

Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring Device At Wrist Against Double Auscultation

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Targeting the Right Ventricle in Pulmonary Hypertension

Evaluating a Blood Pressure Reduction and Weight Loss Program in a Low Income, Ethnically Diverse Population (The Be Fit, Be Well [BFBW] Study)

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Automated Applanation Tonometry

Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults

Physiological Effects of Grape Seed Extract in Diastolic Heart Failure

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

Healthy Living Anson Study

Tailored to You (TTY) Pilot Study

A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy